The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.
about
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular modelThe contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's diseaseGenetic deletion of the GATA1-regulated protein α-synuclein reduces oxidative stress and nitric oxide synthase levels in mature erythrocytesAlpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra.SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's diseaseAlpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress.Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family.Rho GTPase regulation of α-synuclein and VMAT2: implications for pathogenesis of Parkinson's diseaseA novel resource for studying function and dysfunction of α-synuclein: mouse lines for modulation of endogenous Snca gene expression.Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders.Clinical applications involving CNS gene transfer.Parkinson's disease and α-synuclein expressionα-Synuclein and mitochondria: partners in crime?Up-regulation of SNCA gene expression: implications to synucleinopathiesAge-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.α-Synuclein and dopamine at the crossroads of Parkinson's diseaseSynuclein modulation of monoamine transporters.α-Synuclein and mitochondrial dysfunction in Parkinson's disease.Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?The function of α-synuclein.Cellular models for Parkinson's disease.Protein-protein interaction networks identify targets which rescue the MPP+ cellular model of Parkinson's disease.α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease.Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.RNAi-mediated knockdown of HMG CoA reductase enhances gene expression from physiologically regulated low-density lipoprotein receptor therapeutic vectors in vivo.Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line.Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy.Optogenetic Rescue of Locomotor Dysfunction and Dopaminergic Degeneration Caused by Alpha-Synuclein and EKO Genes.Mitophagy in Parkinson's Disease: Pathogenic and Therapeutic Implications.Sustained expression of TDP-43 and FUS in motor neurons in rodent's lifetime.α-Synuclein protects neurons from apoptosis downstream of free-radical production through modulation of the MAPK signalling pathway.A Focus on the Beneficial Effects of Alpha Synuclein and a Re-appraisal of Synucleinopathies.
P2860
Q24656256-C4FE7351-78E9-4FF8-BA4F-12F0766C0A83Q28068464-9D859750-0A11-4E5E-93E5-478D641A9193Q28591516-F1818D58-2893-4122-99F8-4C2BD7FAA6F7Q33658913-042FF250-11BC-45E6-83DE-729FD4C70CB7Q33944220-5E2E9B3C-3161-4BC5-BF26-7019054A81B6Q34534524-64E270E4-9C01-4565-9765-57E79AAF0C36Q35159808-5553F795-815B-4EF9-8AE9-4DB98ED1BA88Q35184890-5ACAF701-FB78-4255-AC69-FAA7CC1D26D1Q35840376-E70A22E7-C6ED-4C59-BB60-181399CFE411Q35877637-2E5A12D9-1008-435C-999B-0FE4779E9A11Q35899850-B89003F3-CCD7-4F9D-980D-310437ACA4B6Q36346542-CA4D6399-63D6-4AFE-8A1C-D049C0DD6CB0Q36983221-DAEE817C-9808-4628-9A23-109F8BE68C2AQ37004246-E1291BBA-959C-4BFE-9257-4D99D064E569Q37701053-CCC28EB3-AECD-4EEC-A9CC-84E5FE67823EQ37801701-15614148-ECDA-4935-BB7E-EFF8CF93CC26Q37852164-F41DF7DF-4B40-43B1-92FD-DBB2043E076AQ38077665-408A4505-93A3-467A-8BFA-8F400816527CQ38128456-F4E62208-72CE-49FF-A1B4-9116312123D3Q38139561-D2C1415D-16FF-4AB2-9B28-35F11678EC90Q38777301-C95F22C4-2EED-4B9C-B3CC-F600A903BF4BQ38816615-072D35AE-3BAA-4610-93C9-8CC4843BB7CEQ39073685-E3063B5B-9DFF-48A3-95F2-63F172FBBE21Q39423921-3656CB28-0042-48E4-A29B-649109C1BCC2Q39499551-FDDB101B-7E21-4308-B2BE-C076921EEC71Q39571308-93770FC6-158A-41E2-A59F-2D7329A731BBQ42014854-59EDB709-28F8-4FA1-87A9-A07F067D1577Q42290602-8227C8FE-3872-4113-A266-7BF66AE64227Q42372932-726BF827-93E9-4AC1-BDED-D768BD9B372EQ42736731-7983097E-90CD-4C90-9DAC-AE184F0E11BBQ47202550-D2BAD2F0-2292-4994-97F2-E1129E6A72AFQ47389795-E3A19628-45EB-4FA7-B21F-7D6A8D831E3E
P2860
The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.
@en
The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.
@nl
type
label
The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.
@en
The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.
@nl
prefLabel
The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.
@en
The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.
@nl
P2093
P2860
P50
P1476
The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.
@en
P2093
Helen C Christian
Lara Lourenco Venda
Nicholas Warrick
Timothy M Fountaine
P2860
P304
P356
10.1111/J.1460-9568.2008.06527.X
P407
P577
2008-11-21T00:00:00Z